Related Experiment Video
Updated: Aug 4, 2026

Measuring Neural Mechanisms Underlying Sleep-Dependent Memory Consolidation During Naps in Early Childhood
Published on: October 2, 2019
Modafinil in the treatment of excessive daytime sleepiness in children
Anna Ivanenko1, Riva Tauman, David Gozal
1Division of Sleep Medicine, Department of Pediatrics, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Insights
Modafinil effectively reduces excessive daytime somnolence (EDS) in children with narcolepsy or idiopathic hypersomnia. This study indicates modafinil is generally safe and well-tolerated for pediatric use in managing sleep disorders.
Area of Science:
- Pediatric Neurology
- Sleep Medicine
- Pharmacology
Background:
- Modafinil is an FDA-approved alerting agent for adult narcolepsy.
- Limited research exists on the long-term safety and efficacy of modafinil in children with excessive daytime somnolence (EDS).
Purpose of the Study:
- To evaluate the effects of modafinil on clinical symptoms of narcolepsy and idiopathic hypersomnia in pediatric patients.
- To assess the safety and tolerability profile of modafinil in children over a prolonged treatment period.
Main Methods:
- A systematic chart review was performed on 13 children (mean age 11.0 years) diagnosed with narcolepsy or idiopathic hypersomnia.
- Children received modafinil treatment for an average of 15.6 months, with dosage adjustments as needed.
- Clinical outcomes were assessed using sleep-wake diaries, and objective measures included nocturnal polysomnography and multiple sleep latency tests (MSLT).
Main Results:
- Approximately 90% of children showed clinical improvement, with reduced sudden sleep attacks.
- Modafinil significantly prolonged mean sleep latency on MSLT (p=0.02), indicating improved alertness.
- While generally well-tolerated, two children experienced exacerbations of seizures or psychotic symptoms; hematological and hepatic functions remained stable.
Conclusions:
- Modafinil demonstrates a modest but significant positive effect on excessive daytime somnolence in children.
- The medication appears to be safe and well-tolerated for long-term use in pediatric patients with narcolepsy and idiopathic hypersomnia.
Background:
Modafinil is an alerting agent approved for the treatment of narcolepsy in adults. There are no studies examining the long-term effects and safety profile of modafinil in children with excessive daytime somnolence (EDS).
Objectives:
To determine the effects of modafinil on clinical manifestations of narcolepsy and idiopathic hypersomnia.
Methods:
A systematic chart review was conducted for 13 children (mean age 11.0+/-5.3 years, six males, 10 with narcolepsy and three with idiopathic hypersomnia) receiving modafinil.
Results:
The mean modafinil dose was 346+/-119 mg/day, with a mean treatment duration of 15.6+/-7.8 months. For approximately 90% of the children treated, parents reported a favorable response with the reduction in sudden sleep attacks, as documented by sleep-wake diaries. One child failed to improve on 400 mg/day modafinil and was switched to methylphenidate. Two other children showed only partial improvement and required additional stimulant medication to control EDS symptoms. Seven children underwent repeated nocturnal polysomnography and multiple sleep latency tests (MSLT). Compared to baseline MSLT measures (mean sleep latency: 6.6+/-3.7 min), modafinil prolonged mean sleep latency (10.2+/-4.8 min, p=0.02) without significant alteration in nocturnal polysomnographic measures. However, a trend towards REM sleep reduction was noted (16.8+/-5.1%TST vs. 11.8+/-6.2%TST). Exacerbation of seizures and psychotic symptoms was reported with modafinil therapy in two children with preexisting conditions. Hematological and hepatic functions assessed every 3 months remained unaltered.
Conclusion:
Modafinil has a modest, yet significant effect on EDS in children and appears to be safe and well tolerated.
More Related Videos
10:02Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
Published on: March 12, 2020
05:59High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
Related Concept Videos
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Narcolepsy
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...